News
In addition to Stifel Nicolaus, Viking Therapeutics also received a Buy from William Blair’s Andy Hsieh in a report issued today. However, yesterday, Citi maintained a Hold rating on Viking ...
4d
MedPage Today on MSNDaily Use of Full-Body Emollients Reduced Eczema Risk in BabiesIn a population not selected for risk, the cumulative incidence of atopic dermatitis at 24 months was 36.1% for those in the daily emollients group versus 43% for those in the control group (relative ...
Reports that the Trevi Fountain will be the next Italian attraction to start charging visitors a fee have sparked controversy ...
Rome switched off the lights of its iconic Trevi Fountain for one hour in a symbolic and urgent appeal for a ceasefire in ...
Rome dimmed the lights of the iconic Trevi Fountain for one hour Friday night in a symbolic call for a ceasefire in the Gaza Strip, following a city council resolution last month that was titled, ...
In a report released yesterday, Faisal Khurshid from Leerink Partners reiterated a Buy rating on Zura Bio. The company’s shares closed yesterday at $1.96. Elevate Your Investing ...
Rome dimmed the lights of the iconic Trevi Fountain for one hour Friday night in a symbolic call for a ceasefire in the Gaza ...
BURBANK, CA (CelebrityAccess) - Gloria Trevi has renewed her global publishing deal with Peermusic and has also signed with Peermusic Neighbouring Rights to collect worldwide (ex-U.S.) for her ...
15d
Zacks Investment Research on MSNWall Street Analysts Predict a 231.05% Upside in Trevi Therapeutics (TRVI): Here's What You Should KnowTrevi Therapeutics, Inc. (TRVI) closed the last trading session at $6.41, gaining 3.9% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set ...
Jasper Therapeutics' valuation falls to $53M following drug development issues, leading to layoffs and a focus shift to treating chronic hives.
Eli Lilly is a leader in the weight loss drug market, generating blockbuster revenue. Viking Therapeutics recently launched a phase 3 trial for its weight loss candidate -- and could have a ...
Investment analysts at Cantor Fitzgerald began coverage on shares of Trevi Therapeutics (NASDAQ:TRVI – Get Free Report) in a research report issued to clients and investors on Tuesday ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results